LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,418,306
تعداد دریافت فایل اصل مقاله11,295,989
Ariafar, Ali, Habibagahi, Mojtaba, Jaberipour, Mansooreh, Khezri, Abdolaziz, Khezri, Mohammad Hadi, Bozorgi, Hale, Hosseini, Ahmad, Razmkhah, Mahboobeh. (1400). Upregulation of Cytotoxic T-Lymphocyte-Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer. سامانه مدیریت نشریات علمی, 46(5), 339-346. doi: 10.30476/ijms.2020.84462.1426
Ali Ariafar; Mojtaba Habibagahi; Mansooreh Jaberipour; Abdolaziz Khezri; Mohammad Hadi Khezri; Hale Bozorgi; Ahmad Hosseini; Mahboobeh Razmkhah. "Upregulation of Cytotoxic T-Lymphocyte-Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer". سامانه مدیریت نشریات علمی, 46, 5, 1400, 339-346. doi: 10.30476/ijms.2020.84462.1426
Ariafar, Ali, Habibagahi, Mojtaba, Jaberipour, Mansooreh, Khezri, Abdolaziz, Khezri, Mohammad Hadi, Bozorgi, Hale, Hosseini, Ahmad, Razmkhah, Mahboobeh. (1400). 'Upregulation of Cytotoxic T-Lymphocyte-Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer', سامانه مدیریت نشریات علمی, 46(5), pp. 339-346. doi: 10.30476/ijms.2020.84462.1426
Ariafar, Ali, Habibagahi, Mojtaba, Jaberipour, Mansooreh, Khezri, Abdolaziz, Khezri, Mohammad Hadi, Bozorgi, Hale, Hosseini, Ahmad, Razmkhah, Mahboobeh. Upregulation of Cytotoxic T-Lymphocyte-Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer. سامانه مدیریت نشریات علمی, 1400; 46(5): 339-346. doi: 10.30476/ijms.2020.84462.1426

Upregulation of Cytotoxic T-Lymphocyte-Associated Protein 4 and Forkhead Box P3 Transcripts in Peripheral Blood of Patients with Bladder Cancer

Iranian Journal of Medical Sciences
مقاله 3، دوره 46، شماره 5، آذر 2021، صفحه 339-346    اصل مقاله (711.78 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2020.84462.1426
نویسندگان
Ali Ariafar1؛ Mojtaba Habibagahi2؛ Mansooreh Jaberipour3؛ Abdolaziz Khezri1؛ Mohammad Hadi Khezri3؛ Hale Bozorgi4؛ Ahmad Hosseini3؛ Mahboobeh Razmkhah* 3
1Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran;
چکیده
Background: Regulatory T cells (Tregs) play a key role in the progression of tumors. These cells express forkhead box P3 (FOXP3) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), which are the potential targets for cancer immunotherapy. The present study aimed to evaluate FOXP3 and CTLA4 transcripts in patients with bladder cancer (BC) compared with healthy individuals.
Methods: Transcripts of CTLA4 and FOXP3 genes in the peripheral blood mononuclear cells (PBMCs) of 50 patients with histologically confirmed BC and 50 healthy individuals were assessed at the Institute for Cancer Research, Shiraz University of Medical Sciences (Shiraz, Iran) during 2014-2016. RNA was extracted from PBMCs, then cDNA was synthesized and subjected to quantitative real-time PCR (qRT-PCR) using appropriate primers. Statistical analysis was performed using SPSS software (version 21.0).
Results: Significantly higher amounts of CTLA4 and FOXP3 gene transcripts were found in the peripheral blood of BC patients compared with healthy individuals. The expression of both genes was significantly higher in patients with non-invasive and grade I/II BC. The median of CTLA4 and FOXP3 transcript expressions was 3.74 and 5.39, respectively, in non-invasive BC patients, which was significant compared with the control group (P=0.0016 and P=0.009, respectively). The median of target gene mRNA expression in grade I/II BC patients was 2.9 for CTLA4 and 6.61 for FOXP3, which was significant compared with the controls (P=0.013 and P=0.0037, respectively).
Conclusion: This study highlights the functional activity of Tregs in early stages of bladder cancer and showed the importance of CTLA4 and FOXP3, when it comes to screening BC.
کلیدواژه‌ها
CTLA4؛ FOXP3؛ Urinary bladder neoplasms؛ T-lymphocytes, Regulatory؛ Immunotherapy
سایر فایل های مرتبط با مقاله
مراجع
  1. Wang CY, Hua R, Liu L, Zhan X, Chen S, Quan S, et al. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine. Cancer Med. 2017;6:689-97. doi: 10.1002/cam4.1023. PubMed PMID: 28205361; PubMed Central PMCID: PMCPMC5345636.
  2. Cao JY, Yin HS, Li HS, Yu XQ, Han X. Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells. Braz J Med Biol Res. 2017;50:e6207. doi: 10.1590/1414-431X20176207. PubMed PMID: 28746469; PubMed Central PMCID: PMCPMC5520222.
  3. Soubra A, Risk MC. Diagnostics techniques in nonmuscle invasive bladder cancer. Indian J Urol. 2015;31:283-8. doi: 10.4103/0970-1591.166449. PubMed PMID: 26604438; PubMed Central PMCID: PMCPMC4626911.
  4. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med. 2006;79:123-30. PubMed PMID: 17940622; PubMed Central PMCID: PMCPMC1994795.
  5. Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, et al. Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998;9:229-37. doi: 10.1016/s1074-7613(00)80605-6. PubMed PMID: 9729043.
  6. Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt Rde W, et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193-219. doi: 10.1146/annurev.immunol.25.022106.141718. PubMed PMID: 17129180.
  7. Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28:401-9. doi: 10.1093/intimm/dxw025. PubMed PMID: 27160722; PubMed Central PMCID: PMCPMC4986235.
  8. Chaudhary B, Elkord E. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel). 2016;4. doi: 10.3390/vaccines4030028. PubMed PMID: 27509527; PubMed Central PMCID: PMCPMC5041022.
  9. Jozwicki W, Brozyna AA, Siekiera J, Slominski AT. Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. Oncotarget. 2016;7:11450-62. doi: 10.18632/oncotarget.7199. PubMed PMID: 26862849; PubMed Central PMCID: PMCPMC4905485.
  10. Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmstrom PU, Totterman TH. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol. 2007;177:353-8. doi: 10.1016/j.juro.2006.08.078. PubMed PMID: 17162090.
  11. Santoni G, Morelli MB, Amantini C, Battelli N. Urinary Markers in Bladder Cancer: An Update. Front Oncol. 2018;8:362. doi: 10.3389/fonc.2018.00362. PubMed PMID: 30245975; PubMed Central PMCID: PMCPMC6137202.
  12. Sethi S, Sethi S, Bluth MH. Clinical Implication of MicroRNAs in Molecular Pathology: An Update for 2018. Clin Lab Med. 2018;38:237-51. doi: 10.1016/j.cll.2018.02.003. PubMed PMID: 29776629.
  13. Salomo K, Huebner D, Boehme MU, Herr A, Brabetz W, Heberling U, et al. Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. J Cancer Res Clin Oncol. 2017;143:1757-69. doi: 10.1007/s00432-017-2433-3. PubMed PMID: 28484844.
  14. Zhang M, Ren B, Li Z, Niu W, Wang Y. Expression of N-Myc Downstream-Regulated Gene 2 in Bladder Cancer and Its Potential Utility as a Urinary Diagnostic Biomarker. Med Sci Monit. 2017;23:4644-9. doi: 10.12659/msm.901610. PubMed PMID: 28953854; PubMed Central PMCID: PMCPMC5627538.
  15. Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife. 2018;7. doi: 10.7554/eLife.32143. PubMed PMID: 29557778; PubMed Central PMCID: PMCPMC5860864.
  16. Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926-30. doi: 10.1126/science.aar3247. PubMed PMID: 29348365; PubMed Central PMCID: PMCPMC6080308.
  17. Jaberipour M, Habibagahi M, Hosseini A, Habibabad SR, Talei A, Ghaderi A. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010;16:547-51. doi: 10.1007/s12253-010-9256-8. PubMed PMID: 20306312.
  18. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012;13:134. doi: 10.1186/1471-2105-13-134. PubMed PMID: 22708584; PubMed Central PMCID: PMCPMC3412702.
  19. BIO-RAD [Internet]. Real-Time PCR Applications Guide. [cited 3 December 2019]. Available from: https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_5279.pdf
  20. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009;16:336-46. doi: 10.1016/j.ccr.2009.08.016. PubMed PMID: 19800578; PubMed Central PMCID: PMCPMC2758294.
  21. Barnes MJ, Griseri T, Johnson AM, Young W, Powrie F, Izcue A. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol. 2013;6:324-34. doi: 10.1038/mi.2012.75. PubMed PMID: 22910217; PubMed Central PMCID: PMCPMC3574974.
  22. Triulzi T, Tagliabue E, Balsari A, Casalini P. FOXP3 expression in tumor cells and implications for cancer progression. J Cell Physiol. 2013;228:30-5. doi: 10.1002/jcp.24125. PubMed PMID: 22674548.
  23. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007;129:1275-86. doi: 10.1016/j.cell.2007.04.034. PubMed PMID: 17570480; PubMed Central PMCID: PMCPMC1974845.
  24. Zhang H, Prado K, Zhang KX, Peek EM, Lee J, Wang X, et al. Biased Expression of the FOXP3Delta3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance. Clin Cancer Res. 2016;22:5349-61. doi: 10.1158/1078-0432.CCR-15-2581. PubMed PMID: 27189164.
  25. Jou YC, Tsai YS, Lin CT, Tung CL, Shen CH, Tsai HT, et al. Foxp3 enhances HIF-1alpha target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation. Oncotarget. 2016;7:65403-17. doi: 10.18632/oncotarget.11395. PubMed PMID: 27557492; PubMed Central PMCID: PMCPMC5323164.
  26. Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A, et al. FOXP3 and survival in urinary bladder cancer. BJU Int. 2011;108:1672-8. doi: 10.1111/j.1464-410X.2010.10020.x. PubMed PMID: 21244603.
  27. Winerdal ME, Krantz D, Hartana CA, Zirakzadeh AA, Linton L, Bergman EA, et al. Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness. Cancer Immunol Res. 2018;6:528-38. doi: 10.1158/2326-6066.CIR-17-0466. PubMed PMID: 29588320.
  28. Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68:267-79. doi: 10.1016/j.eururo.2015.02.032. PubMed PMID: 25824720.
  29. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol. 2014;4:385. doi: 10.3389/fonc.2014.00385. PubMed PMID: 25642417; PubMed Central PMCID: PMCPMC4295550.
  30. van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, et al. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2017;47:385-93. doi: 10.1002/eji.201646583. PubMed PMID: 27873300.
  31. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33:1974-82. doi: 10.1200/JCO.2014.59.4358. PubMed PMID: 25605845; PubMed Central PMCID: PMCPMC4980573.
  32. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16:2861-71. doi: 10.1158/1078-0432.CCR-10-0569. PubMed PMID: 20460488; PubMed Central PMCID: PMCPMC2919850.
  33. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17:1590-8. doi: 10.1016/S1470-2045(16)30496-X. PubMed PMID: 27733243; PubMed Central PMCID: PMCPMC5648054.
  34. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167:397-404. doi: 10.1016/j.cell.2016.08.069. PubMed PMID: 27667683; PubMed Central PMCID: PMCPMC5088716.
  35. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019;25:1233-8. doi: 10.1158/1078-0432.CCR-18-0762. PubMed PMID: 30054281; PubMed Central PMCID: PMCPMC6348141.
  36. Ferrara R, Susini S, Marabelle A. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3(+) Regulatory T Cells (Tregs) in Human Cancers-Letter. Clin Cancer Res. 2019;25:3468. doi: 10.1158/1078-0432.CCR-18-3740. PubMed PMID: 30514779.
آمار
تعداد مشاهده مقاله: 4,708
تعداد دریافت فایل اصل مقاله: 2,810


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب